Clinical Trials Logo

Clinical Trial Summary

The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.


Clinical Trial Description

This is a Phase 1/2, open-label, multi-center, non-randomized, 2-part study in patients with refractory and relapsed AML and refractory myelodysplastic syndrome. Study AB18001 has a multi-stage design. The first part is a dose escalation study that aims to determine the safety, tolerability and pharmacokinetic profiles of consecutive daily intravenous administration of AB8939 in patients with refractory or relapsed AML or patients with refractory myelodysplastic syndrome, and to determine the recommended dose for the second-stage dose expansion study. This dose expansion study aims to determine the schedule for a Phase 2 trial in patients with relapsed/refractory AML and to also provide an early efficacy assessment of AB8939. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05211570
Study type Interventional
Source AB Science
Contact Clinical Study Coordinator
Phone +33(0)147200014
Email [email protected]
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date June 1, 2022
Completion date June 30, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02204085 - A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT05105152 - PLAT-08: A Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML Phase 1
Recruiting NCT04898894 - Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Phase 1
Recruiting NCT04867928 - Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia Phase 2
Recruiting NCT04402541 - Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Active, not recruiting NCT03690154 - A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML Phase 1
Not yet recruiting NCT05317403 - Venetoclax to Augment Epigenetic Modification and Chemotherapy Phase 1
Recruiting NCT03957915 - Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia Early Phase 1
Completed NCT04321161 - Analysis of T Cell Metabolism in Relapsed AML Patients With DLIs and Bicanorm Treatment Early Phase 1
Recruiting NCT04678336 - CD123 Redirected T Cells for AML in Pediatric Subjects Phase 1
Not yet recruiting NCT04716452 - Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Not yet recruiting NCT03053206 - A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia Phase 2
Active, not recruiting NCT03766126 - Lentivirally Redirected CD123 Autologous T Cells in AML Phase 1
Terminated NCT02353143 - Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Terminated NCT02438761 - PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04914845 - KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia Phase 1
Active, not recruiting NCT02768792 - High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML Phase 2
Not yet recruiting NCT03116477 - Study Investigating the Efficacy of the Addition of Crenolanib to Chemotherapy vs Chemotherapy Alone in Patients With R/R FLT3 Mutated AML Phase 3
Not yet recruiting NCT05190471 - A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) Phase 1
Not yet recruiting NCT05124288 - Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways